Related Experiment Video
Updated: Apr 28, 2026

12:13
Ex Situ Normothermic Machine Perfusion of Donor Livers
Published on: May 26, 2015
11.2K
Machine Perfusion Across Marginal Liver Grafts: Benefits and Challenges.
Leandro Sierra1, Maria Ortega Abad2, Maria Saavedra-Martinez3
1Department of Internal Medicine, Cleveland Clinic, Cleveland, OH 44195, USA.
Journal of Personalized Medicine
|April 27, 2026
Summary
Machine perfusion (MP) enhances the use of marginal donor livers, reducing discard rates for steatotic and elderly grafts. This technology improves outcomes and expands the donor pool for liver transplantation.
Area of Science:
- Hepatology
- Transplantation Surgery
- Organ Preservation
Background:
- End-stage liver disease necessitates liver transplantation, but organ shortages lead to graft discard.
- Marginal donor grafts (elderly, steatotic, DCD) face higher discard rates.
- Machine perfusion (MP) offers a solution to expand the usable donor pool.
Purpose of the Study:
- To review evidence for hypothermic (HMP), normothermic (NMP), and normothermic regional perfusion (NRP) in marginal liver grafts.
- To assess MP's impact on graft utilization and patient outcomes.
- To identify barriers and future directions for MP adoption.
Main Methods:
- Narrative review of current evidence on HMP, NMP, and NRP.
- Analysis of MP application in elderly donors, steatotic grafts, DCD donors, and split liver transplantation.
- Examination of MP's role in ex situ therapies and extended preservation.
Main Results:
- MP significantly increases utilization of steatotic grafts (up to eightfold).
- HMP reduces biliary strictures and early allograft dysfunction.
- NMP aids viability assessment and reduces post-reperfusion syndrome; NRP benefits DCD organs.
- MP enables split liver transplantation and shows potential for antiviral therapy.
Conclusions:
- Machine perfusion modalities effectively increase the utilization of marginal donor liver grafts.
- MP improves outcomes, reduces complications, and expands the donor pool.
- Widespread adoption is limited by cost, logistics, and lack of standardized protocols; further multicenter studies are needed.

